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Abstract: C-type natriuretic peptide (CNP) is the major natriuretic peptide of the central nervous 
system and acts via its selective guanylyl cyclase-B (GC-B) receptor to regulate cGMP production 
in neurons, astrocytes and endothelial cells. CNP is implicated in the regulation of neurogenesis, 
axonal bifurcation, as well as learning and memory. Several neurological disorders result in toxic 
concentrations of ammonia (hyperammonaemia), which can adversely affect astrocyte function. 
However, the relationship between CNP and hyperammonaemia is poorly understood. Here, we 
examine the molecular and pharmacological control of CNP in rat C6 glioma cells and rat GPNT 
brain endothelial cells, under conditions of hyperammonaemia. Concentration-dependent inhibi-
tion of C6 glioma cell proliferation by hyperammonaemia was unaffected by CNP co-treatment. 
Furthermore, hyperammonaemia pre-treatment (for 1 h and 24 h) caused a significant inhibition in 
subsequent CNP-stimulated cGMP accumulation in both C6 and GPNT cells, whereas nitric-oxide-
dependent cGMP accumulation was not affected. CNP-stimulated cGMP efflux from C6 glioma 
cells was significantly reduced under conditions of hyperammonaemia, potentially via a mecha-
nism involving changed in phosphodiesterase expression. Hyperammonaemia-stimulated ROS 
production was unaffected by CNP but enhanced by a nitric oxide donor in C6 cells. Extracellular 
vesicle production from C6 cells was enhanced by hyperammonaemia, and these vesicles caused 
impaired CNP-stimulated cGMP signalling in GPNT cells. Collectively, these data demonstrate 
functional interaction between CNP signalling and hyperammonaemia in C6 glioma and GPNT 
cells, but the exact mechanisms remain to be established. 
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The natriuretic peptides are a highly conserved family of peptide hormones, primar-
ily involved in cardiovascular function [1,2]. Whilst Atrial- and B-type natriuretic peptides 
(ANP and BNP) are established as regulators of cardiac function and blood pressure, C-
type natriuretic peptide (CNP) acts as a local regulator in a range of tissues and is the 
predominant natriuretic peptide of the central nervous system [2,3]. CNP acts via its se-
lective membrane-bound guanylyl cyclase receptor-B, GC-B/Npr2, to increase the for-
mation of cGMP in its target tissues [2]. Additionally, CNP also binds to the clearance 
receptor/Npr3, which was thought to act predominantly to remove circulating natriuretic 
peptides for intracellular degradation, but in some tissues been shown to signal through 
G-proteins [4,5]. CNP and GC-B are known to be active in neurons [6], astrocytes and a 
range of CNS-derived cell lines e.g., C6 glioma cells, LHRH neurons [7], and their activity 
is subject to regulation by other peptide hormones (e.g., endothelin) [8]. 
CNP is broadly distributed throughout peripheral and central tissues, where it acts 
predominantly as an autocrine/paracrine regulator [2,3]. Despite this tissue distribution, 
understanding of the main biological functions for CNP remains relatively limited, but 
includes key roles in skeletal growth [9–11], meiosis inhibition [12], and more recently in 
axonal development and bifurcation [13,14]. Whilst Npr2 and PKG signalling are essential 
for bifurcation of sensory neurons, NO-cGMP signalling is not, suggesting compart-
mentalized roles for cGMP [15]. In addition, CNP and cGMP are important for learning 
and memory, by manipulating synaptic plasticity [16]. GC-A and GC-B receptors are ex-
pressed during neurodevelopment, with GC-B thought to play a role in neurogenesis [17], 
but natriuretic peptides also regulate neuronal function in adults. CNP, via the GC-B re-
ceptor, has neuroprotective effects in neonatal brain injury models [18]. Furthermore, re-
duced production of CNP has been observed in patients with neurological disorders, such 
as Parkinson’s disease [19] and epilepsy [20]. This might reflect CNP-dependent changes 
in blood-brain-barrier permeability, as shown in bovine brain microvascular endothelial 
cells and astrocytes [21]. However, understanding of the regulation of CNP and GC-B 
signalling in cells of the nervous system remains limited. 
Astrocytes are the most numerous cell type of the central nervous system, and per-
form a variety of roles including immune mediation, and are regulators of blood-brain-
barrier permeability, in conjunction with endothelial cells and pericytes [22]. A further 
function of astrocytes is that of ammonia detoxification, whereby ammonia is converted 
to glutamine and thus protects the brain from ammonia toxicity [23]. This critical process 
is affected in humans with various neurological conditions, including ageing and Alz-
heimer’s disease [24], where hyperammonaemia (elevated ammonia in the blood) can be 
observed. Additionally, humans and companion animals present with liver abnormalities, 
such as portosystemic shunts, or liver failure (through toxicity or infection), and these can 
lead to the neurological condition of hepatic encephalopathy (HE) [23,24]. This life-threat-
ening condition can present as ataxia, mood alterations, seizures (e.g., status epilepticus), 
neuroinflammation, coma and eventually death [25–27]. A variety of pharmacological 
therapies are used to treat HE and these are typically thought to be safe and beneficial in 
controlling signs [28,29]. However, the evidence for the benefit of treatments targeting 
ammonia in improving signs of HE in people with liver cirrhosis is weak and reduction 
in ammonia concentration is not always associated with significant improvements in HE 
[30]. Furthermore, some drug therapies to treat HE are, themselves, hepatotoxic, which 
further complicates their use in treating a patient with abnormal liver function, or liver 
failure [31]. Several of the clinical signs of HE are associated with a reduction in cGMP 
levels (e.g., cognitive dysfunction, oedema) [27,32–34], which has led to the use of cGMP-
elevating agents as potential therapeutic targets [35,36]. Disrupted cGMP signalling is also 
a feature of Alzheimer’s disease, major depressive disorders, multiple sclerosis and Hun-
tington’s disease [37–40]. Multiple different phosphodiesterases (PDEs) are implicated in 
these disorders, including PDE4, PDE5 and PDE11, which has driven interest in PDE in-
hibitors as therapeutics. However, due to the different subtypes and splice variants, with 
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different selectivities and sensitivities for cAMP and cGMP, there are at least 100 different 
PDE proteins that could potentially be involved in fine-tuning these ubiquitous signalling 
pathways. Therefore, understanding the complex cyclic nucleotide pathways affected by 
these disorders is necessary to improve future treatment options.  
In contrast to ANP and BNP, CNP is only mildly natriuretic, exerting minimal effects 
on blood pressure at the local, rather than systemic, level [5]. Furthermore, various long-
acting analogues of CNP have progressed through clinical trials, for the treatment of rare 
disorders of endochondral ossification (such as achondroplasia), where it is a promising 
treatment for short stature [10,41,42], and CNP can act as an anti-inflammatory agent in 
endothelial cells [43], hepatic fibrosis [44], and is an inflammatory biomarker in Parkin-
son’s disease [45]. Here, we examine the effects of conditions mimicking hyperammonae-
mia on CNP signalling in the well-characterised rat C6 glioma cell line, and the rat brain 
endothelial GPNT cell line to establish how the natriuretic peptide system in these cell 
types could be affected by exposure to neurotoxins and in patients with various neuro-
logical disorders.  
2. Materials and Methods 
2.1. Materials 
Ammonium chloride, atrial natriuretic peptide-28 (referred to as ANP), CNP-22 (re-
ferred to as CNP), sodium nitroprusside (SNP) and all other chemicals were purchased 
from Sigma (Sigma-Aldrich, Poole, UK) unless otherwise stated. IL1β, IL6, TNFα and CRP 
were purchased from R&D Systems (Abingdon, Oxfordshire, UK), and were used as 10 
ng/mL, as described previously [46–48]. Ammonium chloride was used at concentrations 
between 1 and 10 mM, as described previously [49–53]. 
2.2. Cell Culture 
Rat C6 glioma cells, kindly provided by Dr C Thomas (Cancer Research UK, London, 
UK), were grown in monolayer culture in DMEM supplemented with high glucose (4500 
mg/L) containing 10% (v/v) FCS, 1% (v/v) antimycotic/antimicrobial, as previously de-
scribed [54]. Cells were passaged twice weekly and incubated at 37 °C in a humidified 5% 
(v/v) CO2/95% (v/v) air incubator. For experiments, C6 cells were plated at a density of 1.5 
× 105 cells/well in 12-well plates (for RNA extraction and cGMP assays), or 2 × 103 cells/well 
in 96-well plates (for cell proliferation assays and ROS assays). C6 cells were used from a 
range of passages, between 8 and 45. In some instances, images of treated C6 cells were 
taken using a Zeiss Axiovert 135 inverted light microscope. GPNT cells were grown in 
monolayer culture (as described previously [55], and kindly provided by Prof. John 
Greenwood (UCL, London, UK), and cultured in Ham’s F10 with Glutamax 10% (v/v) FCS, 
2 ng/mL bFGF, 80 µg/mL heparin, 1% (v/v) antimycotic/antimicrobial. Cells were plated 
onto collagen I-coated plasticware, and used at a range of passages, between 7 and 20. 
2.3. Crystal Violet Cell Proliferation Assays 
After plating, cells were left to adhere overnight, before stimulation with a range of 
concentrations (0 to 10 mM) of the ammonia donor, NH4Cl, in the absence or presence of 
100 nM CNP, in DMEM supplemented with 1% (v/v) FCS and 1% (v/v) antimycotic/anti-
microbial, to reduce the basal rate of proliferation. At the indicated time points (24, 48 and 
72 h), cells were washed twice with PBS, before being fixed with 4% (w/v) paraformalde-
hyde-containing PBS and stored at 4 °C prior to staining with 0.075% (w/v) crystal violet 
solution for 15min, followed by subsequent washing in water and drying overnight. The 
stained cells were dissolved in 10% (v/v) acetic acid and left for 30 min, before measuring 
the optical density at 595 nm using a Mithras LB940 Multimode Plate reader (Berthold, 
Harpenden, UK). Experiments using GPNT cells also included treatments in the absence 
and presence of 1 mM SNP. 
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2.4. Cyclic GMP Enzyme Immunoassay 
C6 and GPNT cells were allowed to adhere overnight, before being stimulated in 
physiological saline solution (PSS; 127 mM NaCl, 1.8 mM CaCl2, 5 mM KCl, 2 mM MgCl2, 
0.5 nM NaH2PO4, 5 mM NaHCO3, 10 mM glucose, 0.1% (w/v) BSA, 10 mM HEPES, ad-
justed to pH 7.4) with the relevant treatments. All pre-treatment experiments were per-
formed in the absence of 3-isobutyl-1-methylxanthine (IBMX), whereas stimulations were 
performed in the presence of 1 mM IBMX. Reactions were terminated by addition of ice-
cold 100% (v/v) ethanol, and samples were dried down under vacuum as described pre-
viously [56]. For spent media experiments, cells were stimulated with 1% (v/v) FCS-con-
taining DMEM and the relevant treatments in the absence of IBMX, and spent media were 
measured without extraction. Reagents and standards were prepared by using instruc-
tions within the cGMP enzyme-immunoassay kit (R&D Systems, Abingdon, UK). The op-
tical density of each sample at 450 nm was determined using a Berthold Technologies 
Mithras LB940 plate reader with MicroWin 4.40 associated software (Berthold Technolo-
gies, Harpenden, UK). In some cases, data were normalised to facilitate pooling of multi-
ple experiments (for presentation as either % or control, or fold increases. The range of 
cGMP concentrations of these normalised responses ranged from 74 to 361 pmol/mL (for 
CNP), 240 to 725 pmol/mL (for SNP), and 90 to 395 pmol/mL (for 24 h), 198 to 835 pmol/mL 
(for 48 h) and 368 to 1270 pmol/mL (for 72 h) in the spent media experiments; for GPNT 
cGMP experiments, the range of cGMP concentrations for these normalised responses was 
123 to 494 pmol/mL. 
2.5. Tissue Collection, RNA Extraction and Multiplex GeXP RT-qPCR Assay 
Whole brain tissue was collected from 3 male Sprague Dawley rats, placed into foil 
and snap frozen in liquid nitrogen. Total RNA was extracted from brain tissue or cultured 
rat C6 cells using RNAbee reagent (AMS Biotechnology, Abingdon, Oxford, UK), and 
subjected to DNase treatment (Qiagen, Poole, UK), as described previously [57]. RNA con-
centrations were determined using ND-100 spectrophotometer (Nanodrop, Thermo 
Fisher, Hemel Hempstead, UK). Customised GeXP multiplex assays were designed, to 
detect astrocyte and natriuretic peptide gene targets (Npr1, Npr2, Npr3, Gfap, S100b, 
Hmox1, Gad1, Gad2, Fos), or cGMP target genes (Pde1a, Pde4a, Pde4b, Pde4d, Pde5a, Pde7a, 
Pde8a, Pde9a, Pde10a, Pde11a, Mrp4, Mrp5, Prkg1, Prkg2), with Actb used as a housekeeping 
gene for normalisation (Supplemental Table S1). In all assays, 100 ng of total RNA was 
used per sample. Target-specific reverse transcription and PCR amplification was per-
formed as previously described [57] and in accordance with manufacturer’s instructions 
(Beckman Coulter, High Wycombe, UK). Briefly, a master mix was prepared for reverse 
transcription reactions as detailed in the GeXP Starter Kit (AB Sciex, Warrington, Chesh-
ire, UK), and performed using a G-Storm GS1 thermal cycler, using the programme pro-
tocol: 48 °C for 1 min, 42 °C for 60 min, and 95 °C for 5 min. From this, an aliquot of each 
reverse transcription reaction was added to PCR master mix containing GenomeLab kit 
PCR master mix (AB Sciex, Warrington, Cheshire, UK), and Thermoscientific Thermo-
Start Taq DNA polymerase (Thermo Fisher; AB Sciex, Warrington, Cheshire, UK). PCR 
reaction was performed using a 95 °C activation step for 10 min, followed by 35 cycles of 
94 °C for 30 s, 55 °C for 30 s and 70 °C for 60 s. Products were separated and quantified 
using the GeXP CEQ™ 8000 Genetic Analysis System AB Sciex, Warrington, Cheshire, 
UK), and GenomeLab Fragment Analysis software (eXpress Analysis Version 1.0.25, Beck-
man Coulter, UK, Ltd. High Wycombe, Buckinghamshire, UK). 
2.6. Reactive Oxygen Species (ROS) Assays 
C6 cells were cultured on two white-bottomed 96-well plates (2000 cells/well) and 
left overnight to adhere. ROS assays were performed as described previously [58]. DMEM 
was discarded and dihydrorhodamine-1,2,3 (DHR-1,2,3) added to each well for 30 min, 
prior to stimulation with 0.10 nM NH4Cl, 100 nM CNP, 1 mM SNP, NH4Cl+CNP or 
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NH4CL+SNP. All plates were incubated at 37 °C in the dark, prior to absorbance spectros-
copy (using a Wallac 1420 plate-reader, with excitation/emission at 485/520 nm) at various 
timepoints. In some cases, data were normalised to facilitate pooling of multiple experi-
ments (for presentation as fold increases). The range of ROS values for these normalised 
responses varied from 119,860 to 195,038 ALU (for CNP), and from 23,598 to 29,423 ALU 
(for SNP). 
2.7. Extracellular Vesicle Preparation and Flow Cytometry 
Spent media from 0 or 10 mM NH4Cl-treated C6 cells were briefly centrifuged for 5 
min at 4 °C and 3000× g to remove cell debris, before storage at −80 °C to await analysis. 
These supernatants were thawed on ice, and then centrifuged at 4 °C and 17,000× g for 15 
min, before being resuspended in either serum free media (for stimulating GPNT cells), 
or Annexin V buffer (Thermo Fisher Scientific, Dartford, UK) for FACS flow cytometric 
analysis. EVs were stained with or without PE Cy7 Annexin V (to detect exposed phos-
phatidyl serine), from eBioscience (Thermo Fisher Scientific, Dartford, UK), as described 
previously [58]. Samples were acquired for 2 min on a FACS Canto II (BD Biosciences; 
Wokingham, Berkshire, UK), and EVs were counted by reference to enumeration beads 
(Flow count beads; Beckman Coulter, High Wycombe, UK). Data were normalised to fa-
cilitate pooling of multiple experiments (for presentation as fold increases); the range of 
total EV values for these normalised recordings varied from 549 to 2228 events, and 
whereas Cy7 annexin EVs ranged from 77 to 278 events. 
2.8. Data Presentation and Statistical Analysis 
Data are shown as representative or pooled from multiple experiments and normal-
ized (as indicated, and typically presented as means ± SEM, or medians (with 5 to 95% 
confidence intervals). Numerical data were subjected to ANOVA or Mann-Whitney (for 
nonparametric data), followed by Tukey’s or Dunnett’s multiple comparison tests (where 
appropriate), accepting p < 0.05, using in-built equations in GraphPad Prism 7.0a for Mac 
(GraphPad, San Diego, CA, USA). 
3. Results 
3.1. Molecular and Functional Characterisation of Natriuretic Peptides in Rat C6 Glioma Cells 
Previous studies have shown rat C6 glioma cells to respond to natriuretic peptides, 
as determined by cGMP production [59,60]. To confirm the expression and function of the 
natriuretic peptide system in C6 cells, we used multiplex RT-qPCR to examine the expres-
sion of Npr1, Npr2 and the glial cell marker, Gfap, in rat brain tissue and C6 glioma cells. 
As shown (Figure 1A), rat brain expressed transcripts for all three genes, but C6 cells failed 
to express detectable Npr1. We confirmed this natriuretic peptide receptor expression pro-
file at the functional level by stimulating C6 cells with physiological saline solution (PSS) 
containing either 0 or 100 nM ANP or CNP for 1h, in the presence of 1 mM IBMX. As 
shown (Figure 1B), C6 cells failed to respond to ANP, but CNP caused a significant in-
crease in cGMP accumulation (from 10.8 ± 2.1 pmol/mL to 36.0 ± 3.6 pmol/mL, ****p < 
0.0001). In subsequent experiments, CNP showed a concentration-dependent stimulation 
of cGMP accumulation in C6 cells (Figure 1C; from a basal value of 2.5 ± 0.7 pmol/mL to 
78.5 ± 10.7 pmol/mL (***p < 0.001) and 133.5 ± 8.3 pmol/mL (****p < 0.0001) for 10 nM and 
100 nM CNP, respectively; EC50~7 nM). 




Figure 1. Molecular and pharmacological characterization of natriuretic peptide system in rat 
C6 glioma cells. (A) Multiplex RT-qPCR was performed on RNA extracted from rat brain tissue 
or C6 cells. The data shown are mean relative gene expression, normalized to Actb, of 3 to 6 
individual RNA extractions. (B) Total cGMP accumulation in C6 cells treated with 0 or 100 nM 
ANP or CNP for 1h in physiological saline solution containing 1mM IBMX, before measuring 
with a commercially available cGMP-EIA kit (R&D Systems) as described previously. Data 
shown are means ± SEM pooled from three independent experiments, each performed in trip-
licate. ****p < 0.0001, significantly different from basal. (C) Concentration-dependent effects of 
CNP on cGMP accumulation in C6 cells. Cells were treated with the indicated concentrations 
of CNP in PSS containing 1 mM IBMX for 1h. Data shown are means ± SEM, representative of 
three independent experiments, each performed in triplicate. (D) C6 cells were pre-treated in 
media containing 1% (v/v) FCS and 0.10 mM NH4Cl (HA), or 10 ng/mL of either IL1β, IL6, TNFα 
or CRP for 24 h prior to subsequent stimulation with 100 nM CNP in the presence of 1 mM 
IBMX for 15 min. The data shown are means ± SEM of five to twelve individual stimulations, 
expressed as the percentage of the control response to CNP *p < 0.05, significantly different 
from control response to CNP. The dotted line indicates basal cGMP concentration. (E) C6 cells 
were pre-treated in media containing 1% (v/v) FCS and 0, 1, 5 or 10 mM NH4Cl for 24 h prior to 
subsequent stimulation with 100 nM CNP in the presence of 1 mM IBMX for 15 min. The data 
shown are means ± SEM of four to ten independent experiments, each performed in triplicate 
and are expressed as the percentage of the control response to CNP. *p < 0.05, **p < 0.01, signif-
icantly different from control response to CNP. 
Previous studies suggest that hyperammonaemia can reduce cGMP in rat cerebral 
cortices [33]. Therefore, we next examined if conditions associated with neuroinflamma-
tion, such as hyperammonaemia and elevated inflammatory cytokines could affect CNP-
stimulated cGMP accumulation in C6 cells. Cells were pre-treated with either 0 (control), 
10 mM NH4Cl (HA), or with 10ng/mL of either IL1β, IL6, TNFα or CRP for 24 h prior to 
subsequent stimulation with 0 or 100 nM CNP for 15 min in the presence of 1 mM IBMX. 
As shown (Figure 1D), only conditions mimicking hyperammonaemia significantly re-
duced CNP-stimulated cGMP accumulation (to 46.0 ± 8.7% of control, p < 0.05). To deter-
mine whether this inhibitory effect of hyperammonaemia was concentration-dependent, 
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C6 cells were pre-treated with either 0, 1, 5 or 10 mM NH4Cl (HA) for 24 h prior to subse-
quent stimulation with 0 or 100 nM CNP for 15 min in the presence of 1 mM IBMX. The 
effect of hyperammonaemia was shown to be concentration dependent, as C6 cells pre-
treated with 5 mM and 10 mM NH4Cl for 24 h showed a significant reduction in cGMP 
accumulation (to 63.2 ± 16.5% (*p < 0.05) and 62.0 ± 6.4% (**p < 0.01) of control response to 
CNP, for 5 mM and 10 mM NH4Cl, respectively) following a subsequent 15 min stimula-
tion with 100 nM CNP (Figure 1E). 
3.2. Effects of Hyperammonaemia and CNP on Cell Proliferation in Rat C6 Cells 
Having established that C6 cells were functionally responsive to CNP and sensitive 
to conditions of hyperammonaemia, the next experiments examined the effects of expos-
ing C6 cells to increasing concentrations of NH4Cl on cell proliferation. C6 cells were 
plated at 2 × 103 cells/well and left to adhere overnight before transferring to media con-
taining 1% (v/v) FCS and the indicated concentration of NH4Cl (ranging from 0 to 10 mM), 
in the absence or presence of 100 nM CNP. Cells were fixed at the indicated time points 
and cell proliferation was determined by crystal violet assay. As shown (Figure 2A,B and 
D), cell proliferation was not significantly affected by conditions of hyperammonaemia or 
the presence of CNP, after 24 h and 48 h. However, by 72 h (Figure 2C), C6 cells exposed 
to 10 mM NH4Cl showed significantly reduced cell proliferation (from an optical density 
of 0.62 ± 0.04 to 0.43 ± 0.03, *p < 0.05), an effect that was not altered in the presence of 
100nM CNP (from an optical density of 0.63 ± 0.01 to 0.34 ± 0.05, **p < 0.01). Cell morphol-
ogy was assessed by light microscopy after the 72 h treatments, and confirmed cell density 
in the presence of hyperammonaemia, and pronounced thinning of processes and round-
ing up of cells (Figure 2E), effects that were not prevented by the presence of CNP. 




Figure 2. Effects of hyperammonaemia and CNP on cell proliferation and morphology in rat C6 
glioma cells. C6 cells were treated with the indicated concentrations of NH4Cl (log mM) (as an 
NH3 donor) in the absence or presence of 100 nM CNP for (A) 24 h, (B) 48 h or (C) 72 h, before 
being fixed in paraformaldehyde, and stained for crystal violet assay. The data shown are means ± 
SEM pooled from 3 independent experiments, each performed with 8 replicates. *p < 0.05, **p < 
0.01, significantly different from untreated cells. (D) Cell viability in C6 cells in the presence of 0 or 
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100 nM CNP over 72 h. The data shown are means ± SEM pooled from 3 independent experi-
ments, each performed with 8 replicates. (E) Representative microscopy images of C6 cells treated 
for 72 h with 0 (control) or 10 mM NH4Cl (HA), in the presence of 100 nM CNP alone (CNP) or in 
combination (HA+CNP). Arrow heads indicated rounded cells. 
3.3. Effects of Hyperammonaemia on CNP-Stimulated and Sodium Nitroprusside-Stimulated 
cGMP Accumulation in Rat C6 Cells 
Having established that hyperammonaemia, but not inflammatory cytokines, can in-
hibit CNP-stimulated cGMP accumulation, we next examined the kinetics of this re-
sponse. C6 cells were plated at 1.5 × 105 cells/well and left to adhere overnight before 
transferring to media containing 1% (v/v) FCS and either 0 or 10 mM NH4Cl, to create 
conditions of hyperammonaemia, for either 1 h or 24 h. Subsequently, the media were 
replaced with PSS containing 1mM of the non-selective phosphodiesterase inhibitor, 
IBMX, in the absence or presence of 100nM CNP for up to 15 min, prior to termination of 
the reaction and assay for cGMP accumulation. As shown (Figure 3A), CNP caused a 
rapid increase in total cGMP accumulation within 5 min, an effect that was continued by 
15 min. However, pre-treatment in hyperammonaemic conditions caused a significant in-
hibition to CNP-stimulated cGMP accumulation, at both pre-treatment time points 1 h (to 
65.2 ± 11.0% of control response, **p < 0.01) and 24 h (to 66.2 ± 5.3% of control response, *p 
< 0.05)). In addition, the rate of cGMP accumulation appeared to reduce after 5 min of the 
CNP stimulation (Figure 3C), with only the control response to CNP maintaining signifi-
cant linear accumulation (r2 = 0.64***). 
 
Figure 3. Effects of hyperammonaemia on CNP-stimulated cGMP accumulation in rat C6 glioma 
cells. Cells were initially treated in media containing 1% (v/v) FCS and 0 or 10mM NH4Cl (HA) for 
either (A) 1 h or (B) 24 h, prior to subsequent stimulation with 100 nM CNP in the presence of 1 mM 
IBMX for up to 15 min. The data shown are means ± SEM of five to seven independent experiments, 
each performed in triplicate and are expressed as the percentage of the control; *p < 0.05, **p < 0.01, 
significantly different from control response to CNP. (C) Linear accumulation of cGMP between 5 
and 15 min of CNP stimulation. Data shown are normalized to cGMP accumulation after 5 min, 
expressed as means ± SEM of five to seven independent experiments. 
Having shown that cGMP accumulation, mediated via CNP-stimulation of the GC-B 
receptor was sensitive to conditions of hyperammonaemia, similar experiments were per-
formed on C6 cells pre-treated with the identical pre-treatment paradigm, but subse-
quently stimulated with the nitric oxide donor, Sodium Nitroprusside (SNP, 1 mM) for 
up to 15 min. As shown (Figure 4A and B), SNP caused a rapid and sustained increase in 
cGMP accumulation in C6 cells. Furthermore, pre-treatment with 10 mM NH4Cl failed to 
significantly alter the amount of SNP-stimulated cGMP accumulation. In contrast to the 
CNP responses (Figure 3C), the rate of cGMP accumulation was significantly maintained 
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between 5 and 15 min of the SNP stimulation (Figure 4C), with only the HA (24 h) re-
sponse to CNP failing to remain linear (r2 = 0.63). 
 
Figure 4. Effects of hyperammonaemia on SNP-stimulated cGMP accumulation in rat C6 gli-
oma cells. Cells were initially treated in media containing 1% (v/v) FCS and 0 or 10 mM NH4Cl 
(HA) for either (A) 1 h or (B) 24 h, prior to subsequent stimulation with 1 mM SNP in the pres-
ence of 1 mM IBMX for up to 15 min. The data shown are means ± SEM of three independent 
experiments, each performed in triplicate and are expressed as the percentage of the control 
response to SNP. (C) Linear accumulation of cGMP between 5 and 15 min of SNP stimulation. 
Data shown are normalized to cGMP accumulation after 5 min, expressed as means ± SEM of 
three independent experiments. 
3.4. Effects of Hyperammonaemia on CNP-Stimulated cGMP Efflux from Rat C6 Cells 
A reduction in cGMP signalling is associated with several clinical signs linked to Alz-
heimer’s disease [61], major depressive disorders [40], and hepatic encephalopathy [27]. 
To determine whether conditions of hyperammonaemia could cause a similar inhibition 
of extracellular cGMP levels released from C6 cells, we examined the effect of NH4Cl pre-
treatment on cGMP efflux between 24 and 72 h. C6 cells were plated at 1.5 × 105 cells/well, 
and left to adhere overnight before transferring to media containing 1% (v/v) FCS and 
either 0 or 10 mM NH4Cl, in the absence or presence of 100 nM CNP, for up to 72 h. At 
each time point, spent media were removed and stored at −80 °C, prior to assay for extra-
cellular cGMP (as an indication of cGMP efflux). As shown (Figure 5), extracellular cGMP 
concentrations remained unaffected in cells treated in the absence of CNP; however, CNP 
caused significantly enhanced cGMP accumulation at each time point, an effect that was 
inhibited in the presence of hyperammonaemia (from 9.4 ± 1.8-fold to 3.5 ± 0.7-fold (**p < 
0.0001), and from 12.5 ± 2.6-fold to 1.9 ± 0.7-fold (**p < 0.0001), after 48 h and 72 h, respec-
tively). 




Figure 5. Effects of hyperammonaemia on CNP-stimulated cGMP efflux rat C6 glioma cells. C6 
cells were treated in media containing 1% (v/v) FCS and either 0 or 10 mM NH4Cl, (HA) in the 
absence or presence of 100 nM CNP, for up to 72 h. Spent media were collected at the indicated 
time points and analysed for cGMP content. Data shown are means ± SEM of 6 to 8 independent 
experiments, each performed in triplicate, and normalized to basal at each time point. ****p < 
0.0001, significantly different to control response to CNP. 
3.5. Effects of Hyperammonaemia on Expression of Genes Associated with cGMP Regulation in 
Rat C6 Cells 
As the inhibitory effects of hyperammonaemia on cGMP accumulation and efflux 
might reflect alterations to the expression of multiple genes associated with the produc-
tion and metabolism of cGMP, we examined how the expression of 15 cGMP-associated 
transcripts were affected. Total RNA was harvested from the same C6 cells that had been 
treated with 0 or 10 mM NH4Cl for 48 h. Custom-designed multiplex RT-qPCR assays 
were initially performed to examine the expression of cyclic nucleotide phosphodiester-
ases (PDEs), multidrug resistance proteins (MRPs), protein kinase G (PKG) and natriuretic 
peptide receptors (specifically Pde1a, Pde4a, Pde4b, Pde4d, Pde5a, Pde7a, Pde8a, Pde9a, 
Pde10a, Pde11a, Mrp4, Mrp5, Prkg1, Npr2 and Npr3). As shown (Figure 6A–B), condi-
tions of hyperammonaemia caused a significant increase in the expression of Pde5a, 
Pde11a, Mrp4 and Npr3 compared with control cells (from 1.0 ± 0.05 to 1.3 ± 0.1 (*p < 0.05), 
1.0 ± 0.1 to 1.5 ± 0.06 (**p < 0.01), 1.0 ± 0.03 to 1.4 ± 0.14 (*p < 0.05), and 1.0 ± 0.09 to 1.21 ± 
0.1 (*p < 0.05), for Pde5a, Pde11a, Mrp4 and Npr3, respectively). Using an additional mul-
tiplex RT-qPCR assay, we also examined changes in expression of astrocyte enriched tran-
scripts (Gfap, S100, Gad1, Gad2) as well as an inflammatory response gene (Hmox1), and 
an immediate early gene (cFos) in these same RNA samples. As shown (Figure 6B), con-
ditions of hyperammonaemia caused a significant increase in the expression Hmox1, 
Gad1 and Fos compared with control cells (from 1.0 ± 0.06 to 1.6 ± 0.13 (***p < 0.001), 1.0 ± 
0.04 to 1.6 ± 0.08 (****p < 0.0001), and 1.0 ± 0.09 to 2.2 ± 0.24 (**p < 0.01), for Hmox1, Gad1 
and cFos, respectively). 




Figure 6. Effects of hyperammonaemia on cGMP-associated, and astrocyte-enriched gene expres-
sion in rat C6 glioma cells. Cells were initially treated in media containing 1% (v/v) FCS and 0 or 10 
mM NH4Cl (HA) for 48 h, prior to extracting total RNA. Multiplex RT-qPCR assays were per-
formed on RNA extracted from C6 cells to detect (A) transcripts encoding phosphodiesterase en-
zymes, (B) other cGMP-associated genes and astrocyte-enriched transcripts. The data shown are 
the medians (with 5 to 95% confidence intervals) of relative gene expression, normalized to Actb 
and expressed as fold change over basal, from 4 to 12 individual RNA extractions. *p < 0.05, **p < 
0.01, ***p < 0.001, ****p < 0.0001, significantly different from control. 
3.6. Effects of Hyperammonaemia on Reactive Oxygen Species (ROS) Production in Rat C6 Cells 
In several systems, CNP acts as an anti-inflammatory agent [43,44,62]. Part of the 
progression of inflammation is the production of reactive oxygen species, and markers of 
oxidative stress have been observed in patients with hepatic encephalopathy [63]. In the 
next series of experiments, we examined the potential effects of hyperammonaemia, CNP 
and SNP on ROS production in C6 cells. Cells were plated at 2 × 103 cells/well and left to 
adhere overnight before switching to 1% (v/v) FCS-containing media in the presence of 
Dihydrorhodamine-1,2,3 (DHR) for 30 min, before being treated with 0 (control), 10 mM 
NH4Cl (HA), 100 nM CNP or both HA and CNP. As shown (Figure 7A,B), ROS production 
increased over time, and was modestly, but significantly increased under conditions of 
mimicking hyperammonaemia (to 1.18 ± 0.02-fold (****p < 0.0001) and 1.21 ± 0.02-fold 
(****p < 0.0001), for HA and HA+CNP, respectively), an effect that was not altered in the 
presence of CNP. However, when similar experiments were performed, using 1 mM SNP 
instead of CNP (Figure 7C,D), the presence of the nitric oxide donor alone caused a sig-
nificant increase in ROS production that was much greater than that caused by conditions 
mimicking hyperammonaemia (to 2.4 ± 0.09-fold (****p < 0.0001) and 2.80 ± 0.1-fold (****p 
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< 0.0001) for SNP and HA+SNP, respectively). Collectively, these finding suggest that ac-
tivation of the NO/cGMP pathway by SNP in C6 cells can cause significant ROS produc-
tion, even in the absence of conditions of hyperammonaemia. 
 
Figure 7. (A–D). Effects of hyperammonaemia on ROS production in rat C6 glioma cells. Cells 
were pre-treated in media containing 1% (v/v) FCS and 100µM DHR for 30 min prior to stimula-
tion with either 0, 10 mM NH4Cl (HA), 100 nM CNP, 1mM SNP, or combinations of HA+CNP and 
HA+SNP. ROS production was measured every 30 min for 6 h on a plate-reading spectrophotome-
ter at 500 nm, with a final reading taken after 24 h. The data shown are means ± SEM, pooled from 
4 to 6 independent experiments, each performed with 16 replicates (n = 4 to n = 6), and normalised 
to the 24 h control reading. ****p < 0.0001, significantly different from control. 
3.7. Effects of Hyperammonaemia on the Natriuretic Peptide System in Rat GPNT Brain 
Endothelial Cells 
The blood brain barrier consists of astrocytes, pericytes and endothelial cells [64]. In 
order to establish whether the inhibitory effects of hyperammonaemia on natriuretic pep-
tide signalling observed in C6 glioma cells was also seen in rat brain endothelial cells, we 
repeated pharmacological and cellular experiments in rat GPNT brain endothelial cells. 
As shown (Figure 8A), transcripts for both Npr1 and Npr2 receptors were detected by 
multiplex RT-qPCR. This expression profile was confirmed at the pharmacological level, 
with both ANP and CNP stimulating cGMP accumulation in GPNT cells (Figure 8B), with 
CNP activating the GC-B receptor in a concentration-dependent manner (Figure 8C; 
EC50~34 nM). In contrast, 1mM SNP failed to stimulate cGMP accumulation (Figure 8B).  
We next examined how conditions mimicking hyperammonaemia might affect 
GPNT responsiveness to cGMP signalling. In contrast to the observed inhibitory effects of 
hyperammonaemia on cell proliferation in C6 cells, GPNT cell proliferation was not af-
fected by treatment with a range of concentrations of NH4Cl, either in the absence or pres-
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ence of 100nM CNP or 1mM SNP (Figure 8D–F). Finally, we determined whether condi-
tions of hyperammonaemia could alter CNP-stimulated cGMP accumulation in GPNT 
cells. As shown (Figure 8G–H), pre-treatment of GPNT cells with 10mM NH4Cl for either 
1h or 24 h significantly inhibited CNP-stimulated cGMP accumulation (to 54.5 ± 11.5% 
(**p < 0.01) after 1h of hyperammonaemia pre-treatment, and to 58.0 ± 3.7% (****p < 0.001) 
after 24 h of hyperammonaemic conditions. Collectively, these data show GPNT brain 
endothelial cells demonstrate common and distinct sensitivities to conditions of hyperam-
monaemia compared with C6 glioma cells. 
 
Figure 8. Effects of hyperammonaemia on the natriuretic peptide system in rat GPNT brain 
endothelial cells. (A) Multiplex RT-qPCR was performed on RNA extracted from rat brain tis-
sue or GPNT cells. The data shown are mean relative gene expression, normalized to Actb, of 2 
individual RNA extractions. (B) Total cGMP accumulation in GPNT cells treated with 0 or 100 
nM ANP, CNP or 1 mM SNP for 1 h in physiological saline solution containing 1 mM IBMX, 
before assay. Data shown are means ± SEM of triplicate treatments. (C) Concentration-depend-
ent effects of CNP on cGMP accumulation in C6 cells. Cells were treated with the indicated 
concentrations of CNP in PSS containing 1 mM IBMX for 1 h. Data shown are means ± SEM 
pooled from three independent experiments, each performed in triplicate. (D–F) Effects of hy-
perammonaemia and CNP on cell proliferation in GPNT cells. GPNT cells were treated with 
the indicated concentrations of NH4Cl in the absence or presence of 100 nM CNP or 1 nM SNP 
for (D) 24 h, (E) 48 h or (F) 72 h, before being fixed in 4% (w/v) paraformaldehyde and stained 
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for crystal violet assay. The data shown are means ± SEM pooled from 3 independent experi-
ments, each performed with 8 replicates. (G–H) Effects of hyperammonaemia on CNP-stimu-
lated cGMP accumulation in GPNT cells. Cells were initially treated in media containing 1% 
(v/v) FCS and 0 or 10 mM NH4Cl (HA) for either (G) 1 h or (H) 24 h, prior to subsequent stim-
ulation with 100 nM CNP in the presence of 1 mM IBMX for 1 h. The data shown are means ± 
SEM of five to seven independent stimulations, expressed as the percentage of the control re-
sponse to CNP; **p < 0.01, ***p < 0.001, ****p < 0.0001, significantly different from untreated 
(control), or from the control CNP response to CNP (brackets). 
3.8. Effects of Hyperammonaemia on Extracellular Vesicle Production from C6 Cells and Their 
Functional Effects on Natriuretic Peptide Signalling in GPNT Cells 
Extracellular vesicle production is associated with various metabolic, cardiovascular 
and endocrine pathologies [58,65], and their production has been demonstrated from as-
trocytes and C6 cells [66,67]. In addition, rats fed a manipulated diet to induce chronic 
hyperammonaemia, peripherally produce extracellular vesicles that promote neuroin-
flammation in astrocytes [68]. Initially, to establish whether extracellular vesicles produc-
tion from C6 cells was affected by conditions of hyperammonaemia, we stimulated C6 
cells in serum-free media containing 0 or 10 mM NH4Cl for up to 72 h, before harvesting 
the spent media, removing cellular debris, and centrifuging to pellet extracellular vesicles. 
Following staining for exposed phosphatidyl serine with Cy7-labelled Annexin-5, extra-
cellular vesicles were examined by flow cytometry (Figure 8A). As shown (Figure 8B,C), 
hyperammonaemia failed to alter the number of Annexin 5-positive extracellular vesicles 
produced by C6 cells, but did significantly increase the total number of extracellular ves-
icles produced within 24 h (to 124.0 ± 8.0%, *p < 0.05). 
Finally, the functional effects of C6-derived extracellular vesicles (from control or 10 
mM NH4Cl-treated cells) were investigated, by using them to pre-treat GPNT cells for 24 
h, prior to determining the effect on CNP-stimulated cGMP accumulation. As shown (Fig-
ure 9D), 100 nM CNP significantly stimulated cGMP accumulation in GPNT cells treated 
with either control (0 mM) or hyperammonaemia (10 mM)-derived extracellular vesicles 
(to 56.7 ± 8.0 and 29.5 ± 7.3 pmol/mL, ****p < 0.0001 and **p < 0.01, respectively). However, 
GPNT cells pretreated with hyperammonaemia-derived extracellular vesicles generated 
significantly less cGMP in response to CNP (reduced to 52.6 ± 12.8% of control, **p < 0.01). 
These data suggest that hyperammonaemia-derived extracellular vesicles from C6 cells 
functionally inhibit CNP-stimulated cGMP signalling in GPNT cells. 




Figure 9. Effects of hyperammonaemia on extracellular vesicle production from C6 cells, and 
their functional effects on GPNT cells. (A) Extracellular vesicles were harvested from spent me-
dia from C6 cells treated with 0 or 10 mM NH4Cl for up to 72 h. These vesicles were stained 
with Cy7-labelled Annexin-5 and analysed by FACS. Data shown are representative FACS dot 
plots, showing gating parameters. (B,C) Comparison of Annexin-5-positive extracellular vesi-
cles, and total extracellular vesicles from C6 cells treated with 0 or 10 mM NH4Cl. Data shown 
are medians (with 5 to 95% confidence intervals) of events, normalized to % of control treated 
cells, from 3 to 4 independent experiments. *p < 0.05, significantly different from control). (D) 
Effects of C6-derived extracellular vesicles on CNP-stimulated cGMP accumulation in GPNT 
cells. GPNT cells were treated with extracellular vesicles from control or NH4Cl-treated C6 
cells, for 24 h, prior to subsequent stimulation with 100 nM CNP in the presence of 1 mM IBMX 
for 1h. The data shown are means ± SEM from 6 to 9 independent stimulations. ****p < 0.0001, 
**p < 0.01 significantly different from unstimulated; *p < 0.05, significantly different from CNP 
response in C6 EV (0 mM HA) cells. 
4. Discussion 
The CNP/GC-B pathway is the major natriuretic peptide system in the central nerv-
ous system, with CNP having effects on multiple different cell types [2,17], to influence 
key processes such as neurogenesis, axonal bifurcation, learning and memory [13–16]. De-
spite this, understanding of how the CNP/GC-B system in cells of the CNS is affected 
under pathological conditions remains limited. Excess concentrations of ammonia (hyper-
ammonaemia) creates neurotoxicity, and is a feature of neurological disorders such as 
Alzheimer’s disease, ageing, and hepatic encephalopathy [23–25]. Limited studies suggest 
that hyperammonaemia can inhibit CNP signalling in rat cerebral cortices [33] and the 
RBE-4 endothelial cell line [34], but a more detailed investigation of the effects of ammonia 
on CNP is needed. Several previous studies have shown the importance of cGMP signal-
ling in mediating some of the cognitive aspects of major depressive disorders, multiple 
sclerosis, Huntington’s disease, as well as hepatic encephalopathy, and suggests that ma-
nipulation of cGMP/PDE/PKG pathway represents a plausible therapeutic target [27,32–
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40]. Our current study demonstrates that cGMP generation mediated via membrane guan-
ylyl cyclases (specifically GC-B/Npr2) is sensitive to hyperammonaemia, but not inflam-
matory cytokines, by a mechanism that does not appear to affect cGMP generation 
through soluble guanylyl cyclase activation. 
Here, we have utilized the well-characterised C6 glioma cell line (that has phenotypic 
features in common with astrocytes), and GPNT cells (as a model of brain endothelial 
cells) [69]. C6 cells have been widely used as model astrocytes for several decades, and 
despite the limitations of being a tumour cell line (as opposed to primary culture), re-
peated studies have shown that key aspects of astrocyte biology are maintained in their 
gene expression and functional profiles [70,71], making them an appropriate tool for fun-
damental investigations. The expression data within our current study detected tran-
scripts for astrocyte-enriched transcripts in C6 cells, such as Gfap, S100, Gad1 and Gad2, 
albeit with lower abundance than that seen in primary rat brain tissue, which is likely a 
reflection of the undifferentiated nature of C6 cells compared to primary astrocytes. C6 
cells have previously been shown to respond to natriuretic peptides, to stimulate cGMP 
accumulation, and enhance expression of immediate early genes [59,60]. However, it is 
important to acknowledge that key functional differences exist between primary astro-
cytes and C6 glioma cells, including how these two populations of cells metabolise am-
monia [72]. Therefore, it remains to be established as to how the natriuretic peptide system 
is altered by hyperammonaemia in primary astrocytes, as well as in vivo. 
The expression and pharmacology data described herein support previous studies 
that showed that CNP-stimulated cGMP accumulation via the GC-B receptor predomi-
nates, rather than ANP activity via the GC-A receptor [59], and our estimated EC50 values 
for CNP activity in C6 cells (~7 nM) are almost identical to those previously published 
(~10 nM) [8]. Astrocytes interact with endothelial cells to form the blood brain barrier, and 
as such, make an attractive target cell in which to examine the effects of CNP, since its 
function as a regulator of the endothelium has been previously demonstrated [2]. CNP is 
the major natriuretic peptide of the CNS, and the CNP-selective GC-B/Npr2 receptor is 
expressed almost ubiquitously throughout the brain and endothelial cells [2,17]. For these 
reasons, we focused our subsequent investigations on how CNP function might be altered 
under conditions of hyperammonaemia. 
Cyclic GMP signalling in GPNT cells has not been previously reported. Our current 
study reveals presence of both natriuretic peptide guanylyl cyclase receptors (GC-A/Npr1 
and GC-B/Npr2), in contrast to what we observed in C6 glioma cells. However, we failed 
to detect a significant cGMP response to the nitric oxide donor, SNP, in GPNT cells. The 
mechanism for this lack of response to SNP remains to be established but may reflect an 
absence of one of the functional subunits of soluble guanylyl cyclase. The enhanced cGMP 
response to ANP observed in the current study suggests that GPNT cells are likely to ex-
press more GC-A (Npr1) receptors than GC-B (Npr2). Nevertheless, cGMP accumulation 
in response to CNP was robust and concentration-dependent, exhibiting an ~EC50 value 
similar to that observed in C6 glioma cells. Therefore, GPNT cells represent a useful addi-
tional brain endothelial cell line in which to investigate the roles of natriuretic peptides.  
Humans and companion animal patients with neurological disorders are known to 
have elevated levels of inflammatory markers, bile acids and other toxins, in their circu-
lation [23–25]. Of these toxins, one of the most common molecules is ammonia, the con-
centrations of which typically reach pathological levels and cause conditions of hyperam-
monaemia. This is of particular concern with regards to astrocyte function, as these cells 
are the only cell type of the central nervous system capable of metabolizing ammonia, 
essentially detoxifying the CNS [22]. Hyperammonaemia is a mechanistic component of 
several of the clinical signs associated with neurodegenerative disorders, ageing and he-
patic encephalopathy, including cellular oedema, inflammation, abnormal GABA produc-
tion, and inhibition of the cGMP pathway. Our current studies initially examined the po-
tential effect of ammonia (in the form of NH4Cl) on C6 and GPNT cell proliferation. There 
was a significant, concentration-dependent inhibition in C6 cell proliferation after 72 h of 
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hyperammonaemic conditions, an effect that was not prevented by the presence of CNP. 
This inhibitory effect of hyperammonaemia on cell proliferation was not observed in 
GPNT brain endothelial cells, which may suggest a different sensitivity to ammonia, as 
has been seen in a comparison of other cell types [73]. Using the crystal violet assay pre-
vents identification of the specific mechanisms underlying this reduction in cell number, 
such as apoptosis, necrosis, senescence or reduced proliferation. Hyperammonaemia-de-
pendent reductions in cell proliferation and an increase to cellular senescence have previ-
ously been reported in primary rat astrocytes [74,75]. In the current study, we did not 
demonstrate that C6 cells exhibited any form of cell death under conditions of hyperam-
monaemia, but previous studies have found that 10mM NH4Cl caused delayed apoptosis 
after 72 h and 96 h [76]. Therefore, it is possible that prolonged exposure to conditions of 
hyperammonaemia activate apoptosis pathways in C6 glioma cells, but not GPNT cells. 
Previous studies have shown that conditions of hyperammonaemia can cause an at-
tenuation to CNP-stimulated cGMP production in rat cerebral cortex sections and RBE-4 
cells, although the mechanisms involved are not clear [32–34]. Our current findings sug-
gest that CNP-stimulated cGMP accumulation in C6 glioma cells and GPNT brain endo-
thelial cells is subject to inhibition by acute and sustained conditions of hyperammonae-
mia, as CNP-stimulated cGMP accumulation was reduced by approximately 40%. This 
degree of inhibition is similar to that reported in the astrocytic compartment of rat cerebral 
cortex slices [33], and in rat RBE-4 cells [34]. The endogenous GC-B receptors in C6 cells 
exhibited homologous desensitization in the presence of sustained CNP stimulation, as 
indicated by the failure to maintain the initial rate of cGMP accumulation, similar to our 
previous reports in rat GH3 somatolactotropes [77] and murine αT3-1 gonadotropes [78]. 
Interestingly, this key pharmacological process of tachyphylaxis was also present under 
conditions of hyperammonaemia. Whether this inhibitory effect of hyperammonaemia 
represents heterologous desensitization, or an alternative mechanism such as altered re-
ceptor binding properties, is unclear. However, as desensitization was also observed in 
the absence of hyperammonaemia, it is likely that the mechanisms controlling tachyphy-
laxis and ammonia sensitivity, are independent. When similar experiments were per-
formed but using the nitric oxide donor SNP to stimulate cGMP accumulation, the rate of 
cGMP accumulation between 5 and 15 min of stimulation with SNP remained signifi-
cantly linear under almost all conditions. Furthermore, SNP-stimulated cGMP accumula-
tion was insensitive to hyperammonaemia at either 1h or 24 h exposure. Given that ad-
ministration of agents that elevate cGMP can alleviate some of the adverse effects of he-
patic encephalopathy in in vivo models of the disease [35,36], it is tempting to suggest that 
activation of the soluble guanylyl cyclase pathway (through NO) is a better therapeutic 
target than the particulate guanylyl cyclase pathway (through use of analogs of CNP). 
Nitric oxide production in astrocytes has previously been shown to be stimulated by ace-
tylcholine and glutamine [79], thus providing an alternative mechanism through which 
endogenous cGMP production could be stimulated. However, NO-stimulated cGMP pro-
duction in astrocytes has also been shown to lead to cell death in astrocytes [80]. Therefore, 
any therapeutic use that manipulates cGMP levels in patients with hepatic encephalopa-
thy, or indeed other neurological disorders associated with impaired cGMP production, 
needs to consider these potentially undesirable effects. 
We extended our investigations of cGMP signalling in C6 cells to determine whether 
hyperammonaemia could alter CNP-stimulated cGMP efflux, as a reduction in extracel-
lular cGMP concentrations is implicated in the cognitive dysfunction in patients with he-
patic encephalopathy [27], and reduced plasticity in patients with Alzheimer’s disease 
and major depressive disorders [37–40]. Our data show that over a more prolonged time 
period (48 h and 72 h), conditions of hyperammonaemia significantly reduce CNP-stimu-
lated cGMP efflux from C6 cells. This may partially be explained by the findings of the 
previous experiments, which indicated that GC-B receptors may either undergo desensi-
tization or down-regulation under conditions of hyperammonaemia. However, our mul-
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tiplex RT-qPCR assays of cGMP target genes showed an upregulation in transcripts en-
coding Pde5a, and Pde11a. PDE5a is a cGMP-binding, cGMP-specific phosphodiesterase 
[81] whereas as PDE11a acts as a dual-specificity cAMP/cGMP phosphodiesterases [82]; 
therefore, upregulation of either of these enzymes under conditions of hyperammonaemia 
would potentially lead to the observed reduction to extracellular cGMP concentrations. In 
the same multiplex RT-qPCR assays, we also observed a significant increase in the expres-
sion of transcripts for Mrp4 as well as the natriuretic peptide clearance receptor, Npr3. An 
increase in Npr3 expression is consistent with reduced cGMP levels, as it represents a 
mechanism by which CNP is diverted from activating GC-B receptors. Mrp4 encodes the 
multidrug resistance protein 4 (MRP4) that acts to transport cyclic nucleotides out of the 
cell [83]. Our observations are similar to those in rat astrocytes and human cerebral cortex 
from patients with hepatic encephalopathy, where ammonia increased both mRNA and 
protein expression [84]. Upregulation in MRP4 would be expected to increase extracellular 
cGMP, by virtue of increasing the efflux of cGMP in to the extracellular space. Therefore, 
our observation of increased Mpr4 expression under conditions where cGMP concentra-
tions are decreased, could represent some form of attempted compensatory mechanism. 
However, it is important to note that our gene expression data were obtained from C6 
cells in the absence of CNP-stimulation; therefore, further investigations are required to 
determine whether hyperammonaemia alters Pde5a, Pde11a and Npr3 in the presence of 
CNP signalling.  
In addition to examining changes to genes within the natriuretic peptide/cGMP path-
way, we used the same RNA samples to determine the effects of hyperammonaemia on 
the expression of astrocyte-enriched transcripts (Gfap, S100, Gad1, Gad2), a marker of cel-
lular inflammation (Hmox) and an immediate early gene (Fos), in C6 cells. We observed 
robust upregulation of Gad1, Fos and Hmox in C6 cells treated with conditions mimicking 
hyperammonaemia for 48 h but failed to detect any significant alteration in the expression 
of Gfap, S100 or Gad2. Previous studies have reported an inhibitory effect of ammonia on 
Gfap [85,86], although these studies used a different time course to the current study. Sim-
ilarly, S100 protein secretion from cultured astrocytes was enhanced in the presence of 
NH4Cl, but within 24h of treatment [87]. Therefore, it is possible that the lack of significant 
changes to Gfap and S100 expression in the current study reflect a time-dependent sensi-
tivity to hyperammonaemia. Our findings that show an increase in Gad1 expression in C6 
cells treated with NH4Cl are in keeping with recent reports of ammonia-induced hyper-
GABAergic states in zebrafish [88]. Although the gene expression data reported in the 
current study reveal a significant increase in multiple transcripts, we have not examined 
the potential mechanisms by which ammonia regulates gene transcription in C6 glioma 
cells. Previous studies have revealed that conditions of hyperammonaemia can increase 
the production of inflammatory cytokines (TNFα, IL1β, IL6) through pathways that are 
sensitive to NF-κB, ERK and ROS signalling [89]. The potential roles for these pathways 
in mediating the observed changes in gene expression in C6 glioma cells remains to be 
established. 
The increase in Hmox expression in C6 cells, following hyperammonaemia treatment 
for 48 h, is indicative of the inflammatory component of hyperammonaemia (as HMOX 
acts as an anti-inflammatory agent). This upregulation in Hmox expression could be a pro-
tective response to the increase in ROS production observed over a 24 h period, in the 
presence of hyperammonaemia. Co-treatment with CNP was unable to attenuate this in-
crease in ROS, suggesting that CNP does not protect against ROS formation in C6 cells 
(potentially due to the inhibitory effect that hyperammonaemia has on CNP-stimulated 
cGMP production). However, despite the fact that SNP-stimulated cGMP production was 
unaffected by conditions of hyperammonaemia, SNP co-treatment exacerbated hyperam-
monaemia effects on ROS production, leading to a significantly enhanced inflammatory 
response. Therefore, the use of nitric oxide promoting agents as potential anti-inflamma-
tory therapies in conditions of hyperammonaemia may not be appropriate. 
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As well as their contributions to systemic pathologies [58,65], extracellular vesicles 
may represent pivotal regulators of the neuroimmune response [90]. Our findings confirm 
the production of extracellular vesicles from C6 cells and astrocytes [66,67], and represent 
the first demonstration that hyperammonaemia can increase extracellular vesicle produc-
tion from C6 cells. This complements in vivo studies, using a dietary manipulation ap-
proach to induce chronic hyperammonaemia, that showed peripheral production of ex-
tracellular vesicles that promote neuroinflammation in astrocytes [68]. Our functional 
data demonstrate that hyperammonaemia-induced extracellular vesicles from C6 cells are 
inhibitory to CNP-stimulated cGMP accumulation in GPNT cells. Proteomic analysis of 
these vesicles is required to establish the identity of possible antagonists of CNP signal-
ling. Nevertheless, the current observations enhance the understanding of cell signalling 
relationships under conditions of hyperammonaemia. 
Reduced cGMP production in the central nervous system is implicated in cellular 
oedema, cognitive dysfunction, impaired axonal bifurcation and learning deficits [13–
16,27]. Therefore, agents that increase cGMP concentrations remain an attractive approach 
to treat these clinical signs. Our cellular studies suggest that, despite being a potent acti-
vator of cGMP in C6 glioma cells, the use of CNP as one such cGMP-elevating therapy 
may well be compromised by the inhibitory effects that hyperammonemia has on GC-B 
function. Our findings that hyperammonemia can also inhibit CNP signalling in rat brain 
endothelial GPNT cells suggests that cGMP production in multiple components of the 
central nervous system could be impaired by hyperammonaemia. Therefore, the restora-
tion of cGMP signalling remains an intriguing therapeutic target for multiple neurological 
conditions. 
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